Related Experiment Video

Updated: Jun 22, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Identification of inhibitors of checkpoint kinase 1 through template screening

Thomas P Matthews1, Suki Klair, Samantha Burns

  • 1Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.

Journal of Medicinal Chemistry
|July 4, 2009
PubMed

Insights

Researchers identified novel CHK1 inhibitors for cancer therapy. This fragment-based approach yielded promising pyrazolopyridine scaffolds by screening compounds and using X-ray crystallography.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Structural Biology

Background:

  • Checkpoint kinase 1 (CHK1) is a key target in oncology.
  • CHK1 inhibition disrupts cell cycle checkpoints and sensitizes cancer cells to genotoxic treatments, especially in p53-deficient cancers.

Purpose of the Study:

  • To identify novel small molecule inhibitors of CHK1 using a fragment-based approach.
  • To discover and optimize CHK1 inhibitor scaffolds for potential cancer therapies.

Main Methods:

  • Employed template screening and fragment-based drug discovery.
  • Utilized in silico screening, high-concentration biochemical assays, and counter-screening for aggregation.
  • Validated hits using protein-ligand X-ray crystallography and structure-based design.

Main Results:

  • Screened approximately 15,000 compounds, identifying 13 initial template hits.
  • Optimized a purine template hit through iterative structure-based design.
  • Developed submicromolar pyrazolopyridine inhibitors with good ligand efficiency and cellular activity in HT29 colon cancer cells.

Conclusions:

  • Fragment-based screening is effective for identifying CHK1 inhibitor scaffolds.
  • Structure-based design enabled the optimization of initial hits into potent inhibitors.
  • The identified pyrazolopyridines demonstrate potential as therapeutic agents for CHK1-targeted cancer treatments.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Identification of Kinase-substrate Pairs Using High Throughput Screening11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...